Welcome to LookChem.com Sign In|Join Free

CAS

  • or

208399-66-0

Post Buying Request

208399-66-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

208399-66-0 Usage

Description

4-METHOXY-2-METHYLPHENYLBORONIC ACID is an organic compound with the chemical formula C7H9BO3. It is a white solid and is commonly used as a research chemical and a reactant in the synthesis of various biologically active molecules.

Uses

Used in Research and Development:
4-METHOXY-2-METHYLPHENYLBORONIC ACID is used as a research chemical for studying its properties and potential applications in various fields.
Used in Pharmaceutical Industry:
4-METHOXY-2-METHYLPHENYLBORONIC ACID is used as a reactant for the preparation of biologically active molecules, specifically hydroxyphenylnaphthols, which serve as 17?-hydroxysteroid dehydrogenase Type 2 inhibitors. These inhibitors play a crucial role in the development of drugs targeting metabolic disorders and hormonal imbalances.
Used in Chemical Synthesis:
4-METHOXY-2-METHYLPHENYLBORONIC ACID is used as a reactant in the Suzuki reaction, a widely employed method for the formation of carbon-carbon bonds in organic synthesis. This reaction is particularly useful in the synthesis of complex organic molecules, including pharmaceuticals and natural products.
Used in Chemical Industry:
4-METHOXY-2-METHYLPHENYLBORONIC ACID is used as an intermediate in the synthesis of various organic compounds, contributing to the development of new materials and products in the chemical industry.

Check Digit Verification of cas no

The CAS Registry Mumber 208399-66-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,8,3,9 and 9 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 208399-66:
(8*2)+(7*0)+(6*8)+(5*3)+(4*9)+(3*9)+(2*6)+(1*6)=160
160 % 10 = 0
So 208399-66-0 is a valid CAS Registry Number.
InChI:InChI=1/C8H11BO3/c1-6-5-7(12-2)3-4-8(6)9(10)11/h3-5,10-11H,1-2H3

208399-66-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (M2255)  4-Methoxy-2-methylphenylboronic Acid (contains varying amounts of Anhydride)  

  • 208399-66-0

  • 1g

  • 350.00CNY

  • Detail
  • TCI America

  • (M2255)  4-Methoxy-2-methylphenylboronic Acid (contains varying amounts of Anhydride)  

  • 208399-66-0

  • 5g

  • 1,240.00CNY

  • Detail
  • Alfa Aesar

  • (L20112)  4-Methoxy-2-methylbenzeneboronic acid, 98%   

  • 208399-66-0

  • 1g

  • 352.0CNY

  • Detail
  • Alfa Aesar

  • (L20112)  4-Methoxy-2-methylbenzeneboronic acid, 98%   

  • 208399-66-0

  • 5g

  • 1362.0CNY

  • Detail

208399-66-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name (4-methoxy-2-methylphenyl)boronic acid

1.2 Other means of identification

Product number -
Other names 2-methyl-4-methoxy-benzene boronic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:208399-66-0 SDS

208399-66-0Relevant articles and documents

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors

Sang, Yali,Han,Pannecouque, Christophe,De Clercq, Erik,Zhuang, Chunlin,Chen

, (2019/08/20)

Conformational restriction is a promising strategy in the development of DAPY-type non-nucleoside reverse transcriptase inhibitors (NNRTIs). Herein, eighteen thiophene-biphenyl-DAPY derivatives were designed and synthesized as potent HIV-1 NNRTIs in which halogen and methyl groups were introduced to explore the conformationally constrained effects. Molecular docking and dynamic simulation analysis indicated that substituents on different positions of the biphenyl ring induced different dihedral angles and binding conformations, further explaining their anti-viral activities. The 2′-fluoro and 3′-chloro substitutions could form electrostatic or halogen-bonding interactions with adjacent residues of the RT enzyme. The 2′-methyl group contributed to enlarge the dihedral angle of biphenyl ring and was positioned to a space-filling hydrophobic pocket. Notably, compounds 22 and 23 with two methyl groups exhibited potent biological activity against WT HIV-1-infected MT-4 cells (EC50 = 14 and 17 nM, respectively) and RT enzyme (EC50 = 27 and 42 nM, respectively). In particular, 23 exhibited much lower cytotoxicity (CC50 = 264.19 μM) and higher selectivity index (SI = 18,564) than etravirine. Taken together, a rational conformational model for further design of DAPYs is proposed, providing a new guidance for the development of NNRTIs.

Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide

Wang, Pengcheng,Min, Jian,Nwachukwu, Jerome C.,Cavett, Valerie,Carlson, Kathryn E.,Guo, Pu,Zhu, Manghong,Zheng, Yangfan,Dong, Chune,Katzenellenbogen, John A.,Nettles, Kendall W.,Zhou, Hai-Bing

experimental part, p. 2324 - 2341 (2012/05/20)

To develop estrogen receptor (ER) ligands having novel structures and activities, we have explored compounds in which the central hydrophobic core has a more three-dimensional topology than typically found in estrogen ligands and thus exploits the unfilled space in the ligand-binding pocket. Here, we build upon our previous investigations of 7-oxabicyclo[2.2.1]heptene core ligands, by replacing the oxygen bridge with a sulfoxide. These new 7-thiabicyclo[2.2.1] hept-2-ene-7-oxides were conveniently prepared by a Diels-Alder reaction of 3,4-diarylthiophenes with dienophiles in the presence of an oxidant and give cycloadducts with endo stereochemistry. Several new compounds demonstrated high binding affinities with excellent ERα selectivity, but unlike oxabicyclic compounds, which are transcriptional antagonists, most thiabicyclic compounds are potent, ERα-selective agonists. Modeling suggests that the gain in activity of the thiabicyclic compounds arises from their endo stereochemistry that stabilizes an active ER conformation. Further, the disposition of methyl substituents in the phenyl groups attached to the bicyclic core unit contributes to their binding affinity and subtype selectivity.

ERβ ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity

Mewshaw, Richard E.,Edsall Jr., Richard J.,Yang, Cuijian,Manas, Eric S.,Xu, Zhang B.,Henderson, Ruth A.,Keith Jr., James C.,Harris, Heather A.

, p. 3953 - 3979 (2007/10/03)

The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERβ were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERβ, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 208399-66-0